Home › Alnylam Receives Orphan Drug Designation From U.S. Food & Drug Administration For ALN-AT3, An RNAi Therapeutic For The Treatment Of Hemophilia
 

Keywords :   


Alnylam Receives Orphan Drug Designation From U.S. Food & Drug Administration For ALN-AT3, An RNAi Therapeutic For The Treatment Of Hemophilia

2013-09-04 06:05:53| drugdiscoveryonline News Articles

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced recently that the U.S. Food & Drug Administration (FDA) has granted an Orphan Drug Designation to ALN-AT3 as a therapeutic for the treatment of hemophilia B

Tags: the of food administration

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
07.11Hurricane Rafael Graphics
07.11Hurricane Rafael Forecast Discussion Number 16
07.11Hurricane Rafael Wind Speed Probabilities Number 16
07.11Hurricane Rafael Forecast Advisory Number 16
07.11Hurricane Rafael Public Advisory Number 16
07.11Summary for Hurricane Rafael (AT3/AL182024)
07.11Tropical Depression Fourteen-E Graphics
07.11Tropical Depression Fourteen-E Forecast Discussion Number 5
More »